Market Research Logo

Molecular Diagnostics Market Size By Application (Infectious Disease, Blood Screening, Genetic Testing, Oncology Testing), By Technology (PCR, In Situ Hybridization, Chips And Microarrays, Mass Spectrometry, Sequencing, Isothermal Amplification), Industry

Molecular Diagnostics Market Size By Application (Infectious Disease, Blood Screening, Genetic Testing, Oncology Testing), By Technology (PCR, In Situ Hybridization, Chips And Microarrays, Mass Spectrometry, Sequencing, Isothermal Amplification), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Spain, Portugal, Italy, Russia, Denmark, Norway, Sweden, Japan, China, India, Australia, Sri Lanka, Malaysia, Pakistan, Philippines, South Korea, New Zealand, Vietnam, Thailand, Brazil, Mexico, Argentina, Colombia, Chile, Peru, South Africa, Nigeria, Morocco, Egypt, KSA, UAE, Jordan, Qatar, Israel), Application Potential, Competitive Market Share & Forecast, 2018 - 2024

Molecular Diagnostics Market will exceed USD 12.5 billion by 2024; as per a new research report.

Molecular diagnostics has been observed to play significant role in not just identification of infections but also in therapeutic monitoring, patient stratification and drug regimen selection over the past few years. Healthcare providers are increasingly looking for accurate and reliable diagnostic techniques that provide results at highest possible speed. Reliability and accuracy is of highest importance as the errors in diagnosis have serious repercussions. This has created lucrative opportunity for innovative and technologically superior molecular diagnostic techniques.

Increasing accessibility to diagnostic services and consequent increase in availability of molecular diagnostic methods to masses, especially those belong to developing regions will drive the molecular diagnostics market over the forecast period. Robust research and development in the field of molecular diagnostics aimed at the development of superior products, increasing incidences of infectious diseases and rising geriatric population will further support molecular diagnostic market growth. However, the industry face some challenges such as high cost and lack of clear regulatory framework that is expected to impede its growth to some extent.

Infectious disease application segment accounted for more than 45% revenue share in the global molecular diagnostics market in 2017. Infectious diseases including HIV and tuberculosis are responsible for significant mortality and morbidity across the globe and government authorities are trying to curb the economic burden associated with these infectious diseases. As the molecular diagnostics allows better management of infectious diseases and enables early and accurate diagnosis, its demand will augment over the forecast period.

PCR technology segment estimated to witness 6.6% CAGR over the analysis period. The segment currently represents largest portion of molecular diagnostics market and it is likely to retain its position in near future. Ongoing technological advancements such as development of real time PCR will further drive the segment growth.

India Molecular diagnostics market accounted for USD 202.7 million in 2017 and is forecasted to witness robust growth in coming years. Presence of large patient pool suffering from infectious diseases like tuberculosis and HIV has created immense unmet need of superior diagnostic technologies. Rising accessibility to healthcare services and developing healthcare infrastructure will boost the Indian molecular diagnostics market.

Some of the notable players operating in global molecular diagnostics market include Siemens Healthcare, BioMerieux’s, Qiagen Gaithersburg, Roche diagnostics, Cepheid, Agilent (Dako), Johnson and Johnson, GenMark diagnostics, Alere Inc. and Analytik Jena. Key industry players primarily focus on acquisitions, strategic partnerships, and new product development retain their market position.


Chapter 1. Methodology
1.1. Methodology
1.2. Market definition
1.3. Forecast parameters
1.4. Data sources
1.4.1. Secondary
1.4.1.1. Paid sources
1.4.1.2. Unpaid sources
1.4.2. Primary
Chapter 2. Executive Summary
2.1. Molecular diagnostics industry 360º synopsis, 2013 - 2024
2.1.1. Business trends
2.1.2. Application trends
2.1.3. Technology trends
2.1.4. Regional trends
Chapter 3. Molecular Diagnostics Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2013 - 2024
3.3. Industry impact forces
3.3.1. Growth drivers
3.3.1.1. Technological advances and increasing awareness towards early disease diagnosis
3.3.1.2. Escalating demand for POC diagnostics
3.3.1.3. Increasing geriatric population
3.3.1.4. Increasing number of R&D initiatives
3.3.1.5. Upward trend in infectious disease prevalence
3.3.2. Industry pitfalls & challenges
3.3.2.1. Lack of clear and uniform regulatory framework
3.3.2.2. Increasing cost of disease diagnostics
3.4. Growth potential analysis
3.4.1. By application
3.4.2. By technology
3.5. Technology landscape
3.5.1. Product innovation
3.6. Pipeline analysis
3.7. Pricing analysis
3.7.1. Average regional prices
3.8. Porter's analysis
3.9. Competitive landscape, 2017
3.9.1. Strategy dashboard
3.10. PESTEL analysis
Chapter 4. Molecular Diagnostics Market, By Application
4.1. Key segment trends
4.2. Infectious disease
4.2.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.2. Flu
4.2.2.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.3. RSV virus
4.2.3.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.4. Tuberculosis
4.2.4.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.5. Meningitis
4.2.5.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.6. HIV market
4.2.6.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.7. Hepatitis C
4.2.7.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.8. Hepatitis B
4.2.8.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.9. HPV
4.2.9.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.10. STD
4.2.10.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.10.2. Chlamydia
4.2.10.2.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.10.3. Gonorrhea
4.2.10.3.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.10.4. Others
4.2.10.4.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.11. Dengue
4.2.11.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.12. H. Pylori
4.2.12.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.13. TORCH
4.2.13.1. Market size, by region, 2013 - 2024 (USD Million)
4.2.14. Others
4.2.14.1. Market size, by region, 2013 - 2024 (USD Million)
4.3. Blood screening
4.3.1. Market size, by region, 2013 - 2024 (USD Million)
4.4. Genetic testing
4.4.1. Market size, by region, 2013 - 2024 (USD Million)
4.5. Oncology testing
4.5.1. Market size, by region, 2013 - 2024 (USD Million)
Chapter 5. Molecular Diagnostics Market, By Technology
5.1. Key segment trends
5.2. PCR
5.2.1. Market size, by region, 2013 - 2024 (USD Million)
5.3. In-situ hybridization
5.3.1. Market size, by region, 2013 - 2024 (USD Million)
5.4. Chips and microarrays
5.4.1. Market size, by region, 2013 - 2024 (USD Million)
5.5. Mass spectrometry
5.5.1. Market size, by region, 2013 - 2024 (USD Million)
5.6. Sequencing
5.6.1. Market size, by region, 2013 - 2024 (USD Million)
5.7. Isothermal amplification
5.7.1. Market size, by region, 2013 - 2024 (USD Million)
5.8. Others
5.8.1. Market size, by region, 2013 - 2024 (USD Million)
Chapter 6. Molecular Diagnostics Market, By Region
6.1. Key regional trends
6.2. North America
6.2.1. Market size, by country, 2013 - 2024 (USD Million)
6.2.2. Market size, by application, 2013 - 2024 (USD Million)
6.2.2.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.2.2.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.2.3. Market size, by technology, 2013 - 2024 (USD Million)
6.2.4. U.S.
6.2.4.1. Market size, by application, 2013 - 2024 (USD Million)
6.2.4.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.2.4.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.2.4.2. Market size, by technology, 2013 - 2024 (USD Million)
6.2.5. Canada
6.2.5.1. Market size, by application, 2013 - 2024 (USD Million)
6.2.5.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.2.5.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.2.5.2. Market size, by technology, 2013 - 2024 (USD Million)
6.3. Europe
6.3.1. Market size, by country, 2013 - 2024 (USD Million)
6.3.2. Market size, by application, 2013 - 2024 (USD Million)
6.3.2.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.3.2.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.3.3. Market size, by technology, 2013 - 2024 (USD Million)
6.3.4. Germany
6.3.4.1. Market size, by application, 2013 - 2024 (USD Million)
6.3.4.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.3.4.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.3.4.2. Market size, by technology, 2013 - 2024 (USD Million)
6.3.5. UK
6.3.5.1. Market size, by application, 2013 - 2024 (USD Million)
6.3.5.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.3.5.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.3.5.2. Market size, by technology, 2013 - 2024 (USD Million)
6.3.6. France
6.3.6.1. Market size, by application, 2013 - 2024 (USD Million)
6.3.6.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.3.6.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.3.6.2. Market size, by technology, 2013 - 2024 (USD Million)
6.3.7. Italy
6.3.7.1. Market size, by application, 2013 - 2024 (USD Million)
6.3.7.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.3.7.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.3.7.2. Market size, by technology, 2013 - 2024 (USD Million)
6.3.8. Spain
6.3.8.1. Market size, by application, 2013 - 2024 (USD Million)
6.3.8.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.3.8.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.3.8.2. Market size, by technology, 2013 - 2024 (USD Million)
6.3.9. Portugal
6.3.9.1. Market size, by application, 2013 - 2024 (USD Million)
6.3.9.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.3.9.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.3.9.2. Market size, by technology, 2013 - 2024 (USD Million)
6.3.10. Denmark
6.3.10.1. Market size, by application, 2013 - 2024 (USD Million)
6.3.10.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.3.10.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.3.10.2. Market size, by technology, 2013 - 2024 (USD Million)
6.3.11. Norway
6.3.11.1. Market size, by application, 2013 - 2024 (USD Million)
6.3.11.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.3.11.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.3.11.2. Market size, by technology, 2013 - 2024 (USD Million)
6.3.12. Sweden
6.3.12.1. Market size, by application, 2013 - 2024 (USD Million)
6.3.12.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.3.12.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.3.12.2. Market size, by technology, 2013 - 2024 (USD Million)
6.3.13. Russia
6.3.13.1. Market size, by application, 2013 - 2024 (USD Million)
6.3.13.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.3.13.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.3.13.2. Market size, by technology, 2013 - 2024 (USD Million)
6.4. Asia Pacific
6.4.1. Market size, by country, 2013 - 2024 (USD Million)
6.4.2. Market size, by application, 2013 - 2024 (USD Million)
6.4.2.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.4.2.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.4.3. Market size, by technology, 2013 - 2024 (USD Million)
6.4.4. Japan
6.4.4.1. Market size, by application, 2013 - 2024 (USD Million)
6.4.4.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.4.4.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.4.4.2. Market size, by technology, 2013 - 2024 (USD Million)
6.4.5. China
6.4.5.1. Market size, by application, 2013 - 2024 (USD Million)
6.4.5.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.4.5.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.4.5.2. Market size, by technology, 2013 - 2024 (USD Million)
6.4.6. India
6.4.6.1. Market size, by application, 2013 - 2024 (USD Million)
6.4.6.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.4.6.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.4.6.2. Market size, by technology, 2013 - 2024 (USD Million)
6.4.7. Australia
6.4.7.1. Market size, by application, 2013 - 2024 (USD Million)
6.4.7.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.4.7.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.4.7.2. Market size, by technology, 2013 - 2024 (USD Million)
6.4.8. Sri Lanka
6.4.8.1. Market size, by application, 2013 - 2024 (USD Million)
6.4.8.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.4.8.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.4.8.2. Market size, by technology, 2013 - 2024 (USD Million)
6.4.9. Malaysia
6.4.9.1. Market size, by application, 2013 - 2024 (USD Million)
6.4.9.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.4.9.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.4.9.2. Market size, by technology, 2013 - 2024 (USD Million)
6.4.10. Pakistan
6.4.10.1. Market size, by application, 2013 - 2024 (USD Million)
6.4.10.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.4.10.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.4.10.2. Market size, by technology, 2013 - 2024 (USD Million)
6.4.11. Philippines
6.4.11.1. Market size, by application, 2013 - 2024 (USD Million)
6.4.11.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.4.11.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.4.11.2. Market size, by technology, 2013 - 2024 (USD Million)
6.4.12. South Korea
6.4.12.1. Market size, by application, 2013 - 2024 (USD Million)
6.4.12.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.4.12.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.4.12.2. Market size, by technology, 2013 - 2024 (USD Million)
6.4.13. New Zealand
6.4.13.1. Market size, by application, 2013 - 2024 (USD Million)
6.4.13.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.4.13.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.4.13.2. Market size, by technology, 2013 - 2024 (USD Million)
6.4.14. Vietnam
6.4.14.1. Market size, by application, 2013 - 2024 (USD Million)
6.4.14.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.4.14.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.4.14.2. Market size, by technology, 2013 - 2024 (USD Million)
6.4.15. Thailand
6.4.15.1. Market size, by application, 2013 - 2024 (USD Million)
6.4.15.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.4.15.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.4.15.2. Market size, by technology, 2013 - 2024 (USD Million)
6.5. Latin America
6.5.1. Market size, by country, 2013 - 2024 (USD Million)
6.5.2. Market size, by application, 2013 - 2024 (USD Million)
6.5.2.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.5.2.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.5.3. Market size, by technology, 2013 - 2024 (USD Million)
6.5.4. Brazil
6.5.4.1. Market size, by application, 2013 - 2024 (USD Million)
6.5.4.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.5.4.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.5.4.2. Market size, by technology, 2013 - 2024 (USD Million)
6.5.5. Mexico
6.5.5.1. Market size, by application, 2013 - 2024 (USD Million)
6.5.5.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.5.5.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.5.5.2. Market size, by technology, 2013 - 2024 (USD Million)
6.5.6. Argentina
6.5.6.1. Market size, by application, 2013 - 2024 (USD Million)
6.5.6.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.5.6.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.5.6.2. Market size, by technology, 2013 - 2024 (USD Million)
6.5.7. Colombia
6.5.7.1. Market size, by application, 2013 - 2024 (USD Million)
6.5.7.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.5.7.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.5.7.2. Market size, by technology, 2013 - 2024 (USD Million)
6.5.8. Chile
6.5.8.1. Market size, by application, 2013 - 2024 (USD Million)
6.5.8.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.5.8.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.5.8.2. Market size, by technology, 2013 - 2024 (USD Million)
6.5.9. Peru
6.5.9.1. Market size, by application, 2013 - 2024 (USD Million)
6.5.9.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.5.9.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.5.9.2. Market size, by technology, 2013 - 2024 (USD Million)
6.6. Africa
6.6.1. Market size, by country, 2013 - 2024 (USD Million)
6.6.2. Market size, by application, 2013 - 2024 (USD Million)
6.6.2.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.6.2.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.6.3. Market size, by technology, 2013 - 2024 (USD Million)
6.6.4. South Africa
6.6.4.1. Market size, by application, 2013 - 2024 (USD Million)
6.6.4.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.6.4.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.6.4.2. Market size, by technology, 2013 - 2024 (USD Million)
6.6.5. Nigeria
6.6.5.1. Market size, by application, 2013 - 2024 (USD Million)
6.6.5.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.6.5.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.6.5.2. Market size, by technology, 2013 - 2024 (USD Million)
6.6.6. Morocco
6.6.6.1. Market size, by application, 2013 - 2024 (USD Million)
6.6.6.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.6.6.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.6.6.2. Market size, by technology, 2013 - 2024 (USD Million)
6.6.7. Egypt
6.6.7.1. Market size, by application, 2013 - 2024 (USD Million)
6.6.7.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.6.7.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.6.7.2. Market size, by technology, 2013 - 2024 (USD Million)
6.7. Middle East
6.7.1. Market size, by country, 2013 - 2024 (USD Million)
6.7.2. Market size, by application, 2013 - 2024 (USD Million)
6.7.2.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.7.2.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.7.3. Market size, by technology, 2013 - 2024 (USD Million)
6.7.4. Saudi Arabia
6.7.4.1. Market size, by application, 2013 - 2024 (USD Million)
6.7.4.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.7.4.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.7.4.2. Market size, by technology, 2013 - 2024 (USD Million)
6.7.5. UAE
6.7.5.1. Market size, by application, 2013 - 2024 (USD Million)
6.7.5.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.7.5.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.7.5.2. Market size, by technology, 2013 - 2024 (USD Million)
6.7.6. Jordan
6.7.6.1. Market size, by application, 2013 - 2024 (USD Million)
6.7.6.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.7.6.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.7.6.2. Market size, by technology, 2013 - 2024 (USD Million)
6.7.7. Qatar
6.7.7.1. Market size, by application, 2013 - 2024 (USD Million)
6.7.7.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.7.7.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.7.7.2. Market size, by technology, 2013 - 2024 (USD Million)
6.7.8. Israel
6.7.8.1. Market size, by application, 2013 - 2024 (USD Million)
6.7.8.1.1. Market size, by infectious disease, 2013 - 2024 (USD Million)
6.7.8.1.1.1. Market size, by STDs, 2013 - 2024 (USD Million)
6.7.8.2. Market size, by technology, 2013 - 2024 (USD Million)
Chapter 7. Company Profiles
7.1. Abbott Molecular
7.1.1. Business overview
7.1.2. Financial data
7.1.3. Product landscape
7.1.4. Strategic outlook
7.1.5. SWOT analysis
7.2. Agilent (Dako)
7.2.1. Business overview
7.2.2. Financial data
7.2.3. Product landscape
7.2.4. Strategic outlook
7.2.5. SWOT analysis
7.3. Alere Inc.
7.3.1. Business overview
7.3.2. Financial data
7.3.3. Product landscape
7.3.4. Strategic outlook
7.3.5. SWOT analysis
7.4. Analytik Jena AG
7.4.1. Business overview
7.4.2. Financial data
7.4.3. Product landscape
7.4.4. Strategic outlook
7.4.5. SWOT analysis
7.5. Becton, Dickinson and Company
7.5.1. Business overview
7.5.2. Financial data
7.5.3. Product landscape
7.5.4. Strategic outlook
7.5.5. SWOT analysis
7.6. Biocartis Group NV
7.6.1. Business overview
7.6.2. Financial data
7.6.3. Product landscape
7.6.4. Strategic outlook
7.6.5. SWOT analysis
7.7. BioFire Diagnostics
7.7.1. Business overview
7.7.2. Financial data
7.7.3. Product landscape
7.7.4. Strategic outlook
7.7.5. SWOT analysis
7.8. Biomerieux
7.8.1. Business overview
7.8.2. Financial data
7.8.3. Product landscape
7.8.4. Strategic outlook
7.8.5. SWOT analysis
7.9. Bio-Rad Laboratories
7.9.1. Business overview
7.9.2. Financial data
7.9.3. Product landscape
7.9.4. Strategic outlook
7.9.5. SWOT analysis
7.10. Bio-Techne
7.10.1. Business overview
7.10.2. Financial data
7.10.3. Strategic outlook
7.10.4. SWOT analysis
7.11. Cepheid
7.11.1. Business overview
7.11.2. Financial data
7.11.3. Product landscape
7.11.4. Strategic outlook
7.11.5. SWOT analysis
7.12. Cleaver Scientific
7.12.1. Business overview
7.12.2. Product landscape
7.12.3. SWOT analysis
7.13. CombiMatrix
7.13.1. Business overview
7.13.2. Financial data
7.13.3. Product landscape
7.13.4. Strategic outlook
7.13.5. SWOT analysis
7.14. Danaher Corporation
7.14.1. Business overview
7.14.2. Financial data
7.14.3. Product landscape
7.14.4. Strategic outlook
7.14.5. SWOT analysis
7.15. GenMark Diagnostics
7.15.1. Business overview
7.15.2. Financial data
7.15.3. Product landscape
7.15.4. Strategic outlook
7.16. Genomic Health, Inc.
7.16.1. Business overview
7.16.2. Financial data
7.16.3. Product landscape
7.16.4. Strategic outlook
7.16.5. SWOT analysis
7.17. Heal Force
7.17.1. Business overview
7.17.2. Financial data
7.17.3. Product landscape
7.17.4. SWOT analysis
7.18. Hercuvan Lab Systems
7.18.1. Business overview
7.18.2. Financial data
7.18.3. Product landscape
7.18.4. Strategic outlook
7.18.5. SWOT analysis
7.19. Hologic (Gen Probe)
7.19.1. Business overview
7.19.2. Financial data
7.19.3. Product landscape
7.19.4. Strategic outlook
7.19.5. SWOT analysis
7.20. HTG Molecular Diagnostics
7.20.1. Business overview
7.20.2. Financial data
7.20.3. Product landscape
7.20.4. Strategic outlook
7.20.5. SWOT analysis
7.21. Johnson & Johnson
7.21.1. Business overview
7.21.2. Financial data
7.21.3. Product landscape
7.21.4. Strategic outlook
7.21.5. SWOT analysis
7.22. MDxHealth
7.22.1. Business overview
7.22.2. Financial data
7.22.3. Product landscape
7.22.4. Strategic outlook
7.22.5. SWOT analysis
7.23. Myriad Genetics, Inc.
7.23.1. Business overview
7.23.2. Financial data
7.23.3. Product landscape
7.23.4. Strategic outlook
7.23.5. SWOT analysis
7.24. Novartis (Grifols)
7.24.1. Business overview
7.24.2. Financial data
7.24.3. Product landscape
7.24.4. Strategic outlook
7.24.5. SWOT analysis
7.25. Qiagen Gaithersburg, Inc.
7.25.1. Business overview
7.25.2. Financial data
7.25.3. Product landscape
7.25.4. Strategic outlook
7.25.5. SWOT analysis
7.26. Roche Diagnostics
7.26.1. Business overview
7.26.2. Financial data
7.26.3. Product landscape
7.26.4. Strategic outlook
7.26.5. SWOT analysis
7.27. Rosetta Genomics
7.27.1. Business overview
7.27.2. Financial data
7.27.3. Product landscape
7.27.4. Strategic outlook
7.27.5. SWOT analysis
7.28. SCILOGEX, LLC
7.28.1. Business overview
7.28.2. Financial data
7.28.3. Product landscape
7.28.4. Strategic outlook
7.28.5. SWOT analysis
7.29. Siemens Healthcare
7.29.1. Business overview
7.29.2. Financial data
7.29.3. Product landscape
7.29.4. Strategic outlook
7.29.5. SWOT analysis
7.30. Sysmex
7.30.1. Business overview
7.30.2. Financial data
7.30.3. Product landscape
7.30.4. Strategic outlook
7.30.5. SWOT analysis
Data Tables
TABLE 1. Molecular diagnostics industry 360 degree synopsis, 2013 - 2024
TABLE 2. Global molecular diagnostics market, 2013 - 2024 (USD Million)
TABLE 3. Global molecular diagnostics market, by application, 2013 - 2024 (USD Million)
TABLE 4. Global molecular diagnostics market, by technology, 2013 - 2024 (USD Million)
TABLE 5. Global molecular diagnostics market, by region, 2013 - 2024 (USD Million)
TABLE 6. Industry impact forces
TABLE 7. Molecular diagnostics market, pipeline analysis
TABLE 8. Infectious disease market size, by region, 2013 - 2024 (USD Million)
TABLE 9. Flu market size, by region, 2013 - 2024 (USD Million)
TABLE 10. RSV virus market size, by region, 2013 - 2024 (USD Million)
TABLE 11. Tuberculosis market size, by region, 2013 - 2024 (USD Million)
TABLE 12. Meningitis market size, by region, 2013 - 2024 (USD Million)
TABLE 13. HIV market size, by region, 2013 - 2024 (USD Million)
TABLE 14. Hepatitis C market size, by region, 2013 - 2024 (USD Million)
TABLE 15. Hepatitis B market size, by region, 2013 - 2024 (USD Million)
TABLE 16. HPV market size, by region, 2013 - 2024 (USD Million)
TABLE 17. STD market size, by region, 2013 - 2024 (USD Million)
TABLE 18. Chlamydia market size, by region, 2013 - 2024 (USD Million)
TABLE 19. Gonorrhea market size, by region, 2013 - 2024 (USD Million)
TABLE 20. Others market size, by region, 2013 - 2024 (USD Million)
TABLE 21. Dengue market size, by region, 2013 - 2024 (USD Million)
TABLE 22. H. Pylori market size, by region, 2013 - 2024 (USD Million)
TABLE 23. TORCH market size, by region, 2013 - 2024 (USD Million)
TABLE 24. Others market size, by region, 2013 - 2024 (USD Million)
TABLE 25. Blood screening market size, by region, 2013 - 2024 (USD Million)
TABLE 26. Genetic testing market size, by region, 2013 - 2024 (USD Million)
TABLE 27. Oncology testing market size, by region, 2013 - 2024 (USD Million)
TABLE 28. PCR testing market size, by region, 2013 - 2024 (USD Million)
TABLE 29. In Situ Hybridization market size, by region, 2013 - 2024 (USD Million)
TABLE 30. Chips and microarrays testing market size, by region, 2013 - 2024 (USD Million)
TABLE 31. Mass spectrometry testing market size, by region, 2013 - 2024 (USD Million)
TABLE 32. Sequencing testing market size, by region, 2013 - 2024 (USD Million)
TABLE 33. Isothermal amplification testing market size, by region, 2013 - 2024 (USD Million)
TABLE 34. Others market size, by region, 2013 - 2024 (USD Million)
TABLE 35. North America molecular diagnostics market size, by country, 2013 - 2024 (USD Million)
TABLE 36. North America molecular diagnostics market size, by application, 2013 - 2024 (USD Million)
TABLE 37. North America molecular diagnostics market size, by infectious disease, 2013 - 2024 (USD Million)
TABLE 38. North America molecular diagnostics market size, by STDs, 2013 - 2024 (USD Million)
TABLE 39. North America molecular diagnostics market size, by technology, 2013 - 2024 (USD Million)
TABLE 40. U.S. molecular diagnostics market size, by application, 2013 - 2024 (USD Million)
TABLE 41. U.S. molecular diagnostics market size, by infectious disease, 2013 - 2024 (USD Million)
TABLE 42. U.S. molecular diagnostics market size, by STDs, 2013 - 2024 (USD Million)
TABLE 43. U.S. molecular diagnostics market size, by technology, 2013 - 2024 (USD Million)
TABLE 44. Canada molecular diagnostics market size, by application, 2013 - 2024 (USD Million)
TABLE 45. Canada molecular diagnostics market size, by infectious disease, 2013 - 2024 (USD Million)
TABLE 46. Canada molecular diagnostics market size, by STDs, 2013 - 2024 (USD Million)
TABLE 47. Canada molecular diagnostics market size, by technology, 2013 - 2024 (USD Million)
TABLE 48. Europe molecular diagnostics market size, by country, 2013 - 2024 (USD Million)
TABLE 49. Europe molecular diagnostics market size, by application, 2013 - 2024 (USD Million)
TABLE 50. Europe molecular diagnostics market size, by infectious disease, 2013 - 2024 (USD Million)
TABLE 51. Europe molecular diagnostics market size, by STDs, 2013 - 2024 (USD Million)
TABLE 52. Europe molecular diagnostics market size, by technology, 2013 - 2024 (USD Million)
TABLE 53. Germany molecular diagnostics market size, by application, 2013 - 2024 (USD Million)
TABLE 54. Germany molecular diagnostics market size, by infectious disease, 2013 - 2024 (USD Million)
TABLE 55. Germany molecular diagnostics market size, by STDs, 2013 - 2024 (USD Million)
TABLE 56. Germany molecular diagnostics market size, by technology, 2013 - 2024 (USD Million)
TABLE 57. UK molecular diagnostics market size, by application, 2013 - 2024 (USD Million)
TABLE 58. UK molecular diagnostics market size, by infectious disease, 2013 - 2024 (USD Million)
TABLE 59. UK molecular diagnostics market size, by STDs, 2013 - 2024 (USD Million)
TABLE 60. UK molecular diagnostics market size, by technology, 2013 - 2024 (USD Million)
TABLE 61. France molecular diagnostics market size, by application, 2013 - 2024 (USD Million)
TABLE 62. France molecular diagnostics market size, by infectious disease, 2013 - 2024 (USD Million)
TABLE 63. France molecular diagnostics market size, by STDs, 2013 - 2024 (USD Million)
TABLE 64. France molecular diagnostics market size, by technology, 2013 - 2024 (USD Million)
TABLE 65. Italy molecular diagnostics market size, by application, 2013 - 2024 (USD Million)
TABLE 66. Italy molecular diagnostics market size, by infectious disease, 2013 - 2024 (USD Million)
TABLE 67. Italy molecular diagnostics market size, by STDs, 2013 - 2024 (USD Million)
TABLE 68. Italy molecular diagnostics market size, by technology, 2013 - 2024 (USD Million)
TABLE 69. Spain molecular diagnostics market size, by application, 2013 - 2024 (USD Million)
TABLE 70. Spain molecular diagnostics market size, by infectious disease, 2013 - 2024 (USD Million)
TABLE 71. Spain molecular diagnostics market size, by STDs, 2013 - 2024 (USD Million)
TABLE 72. Spain molecular diagnostics market size, by technology, 2013 - 2024 (USD Million)
TABLE 73. Portugal molecular diagnostics market size, by application, 2013 - 2024 (USD Million)
TABLE 74. Portugal molecular diagnostics market size, by infectious disease, 2013 - 2024 (USD Million)
TABLE 75. Portugal molecular diagnostics market size, by STDs, 2013 - 2024 (USD Million)
TABLE 76. Portugal molecular diagnostics market size, by technology, 2013 - 2024 (USD Million)
TABLE 77. Denmark molecular diagnostics market size, by application, 2013 - 2024 (USD Million)
TABLE 78. Denmark molecular diagnostics market size, by infectious disease, 2013 - 2024 (USD Million)
TABLE 79. Denmark molecular diagnostics market size, by STDs, 2013 - 2024 (USD Million)
TABLE 80. Denmark molecular diagnostics market size, by technology, 2013 - 2024 (USD Million)
TABLE 81. Norway molecular diagnostics market size, by application, 2013 - 2024 (USD Million)
TABLE 82. Norway molecular diagnostics market size, by infectious disease, 2013 - 2024 (USD Million)
TABLE 83. Norway molecular diagnostics market size, by STDs, 2013 - 2024 (USD Million)
TABLE 84. Norway molecular diagnostics market size, by technology, 2013 - 2024 (USD Million)
TABLE 85. Sweden molecular diagnostics market size, by application, 2013 - 2024 (USD Million)
TABLE 86. Sweden molecular diagnostics market size, by infectious disease, 2013 - 2024 (USD Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report